SEC Form 4 · accession 0000899243-17-011274
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — Chief Financial Officer
Period of report
Apr 28, 2017
Accepted (ET)
May 1, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $19.44 | Apr 28, 2017 | A | 270,000 | A | — | Apr 28, 2027 | Common Stock | 270,000 | 270,000 | D |
Explanation of responses
- F1The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 28, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.